According to the Centers for Disease Control and Prevention (CDC), approximately 42% of Americans are obese, and 65% say willpower alone isn’t enough for most people who are trying to lose weight.

Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy ...

Hims & Hers last week announced a copycat version of the Wegovy pill that would cost $49 for the first month and $99 per month after on a five-month plan. That sent the stock surging last week, but ...

Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.

An experimental combo drug from Novo Nordisk leads to more weight loss than semaglutide alone, according to late-stage trial data.

In a new review from top dietitians in Australia, it appears very few global trials of GLP-1s have taken into consideration ...

Hims & Hers says it will stop selling a low-cost copy of a new weight-loss pill made by Novo Nordisk, after federal officials raised concerns that the product may violate drug laws.

Semaglutide is the active ingredient in Ozempic and Wegovy. It’s a synthetic form of GLP-1, a hormone that regulates our ...

As Novo Nordisk surges and Hims & Hers tanks, analysts see relief for Novo from competition in the compounded pill segment ...

Dr Donald Grant from The Independent Pharmacy revealed six health things some may believe about weight loss jabs that aren't true.

The Wegovy and Ozempic maker seeks a ban on the telehealth provider offering knockoffs of its weight-loss and obesity ...

The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill.